| Market Cap | 0.98K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -55.19M | Forward P/E | 0.00 | EPS next Y | - | 50D Avg Chg | -99.00% |
| Sales | 659k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -100.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 3.00 | Quick Ratio | 1.40 | Shares Outstanding | 4.90M | 52W Low Chg | 100.00% |
| Insider Own | 5.46% | ROA | -41.86% | Shares Float | 4.63M | Beta | 3.08 |
| Inst Own | 0.29% | ROE | -192.97% | Shares Shorted/Prior | 332.30K/382.68K | Price | 0.00020 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 11,478 | Target Price | 21.00 |
| Oper. Margin | -4,683.01% | Earnings Date | Mar 15 | Volume | 5,685 | Change | 0.00% |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on November 22, 2022.
